Isis Accused Of Hiding Cholesterol Drug's Safety Risks
A putative class action launched Friday in California federal court alleges Isis Pharmaceuticals Inc. misled investors over the safety and effectiveness of cholesterol disorder treatment Kynamro, which U.S. Food and Drug...To view the full article, register now.
Already a subscriber? Click here to view full article